HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: R600010-MCP200v1 5/10/1745    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casiano, C. A. Articles by Tan, E. M. Search for Related Content PubMed PubMed Citation Articles by Casiano, C. A. Articles by Tan, E. M. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:1745-1759, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Cancer

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer^*

Carlos A. Casiano^,,¶, Melanie Mediavilla-Varela and Eng M. Tan^||

From the Center for Health Disparities Research and Department of Biochemistry and Microbiology and Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California 92350 and the ^|| W. M. Keck Autoimmune Disease Center, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037

The recognition that human tumors stimulate the production of autoantibodies against autologous cellular proteins called tumor-associated antigens (TAAs) has opened the door to the possibility that autoantibodies could be exploited as serological tools for the early diagnosis and management of cancer. Cancer-associated autoantibodies are often driven by intracellular proteins that are mutated, modified, or aberrantly expressed in tumor cells and hence are regarded as immunological reporters that could help uncover molecular events underlying tumorigenesis. Emerging evidence suggests that each type of cancer might trigger unique autoantibody signatures that reflect the nature of the malignant process in the affected organ. The advent of novel genomic, proteomic, and high throughput approaches has accelerated interest in the serum autoantibody repertoire in human cancers for the discovery of candidate TAAs. The use of individual anti-TAA autoantibodies as diagnostic or prognostic tools has been tempered by their low frequency and heterogeneity in most human cancers. However, TAA arrays comprising several antigens significantly increase this frequency and hold great promise for the early detection of cancer, monitoring cancer progression, guiding individualized therapeutic interventions, and identification of novel therapeutic targets. Our recent studies suggest that the implementation of TAA arrays in screening programs for the diagnosis of prostate cancer and other cancers should be preceded by the optimization of their sensitivity and specificity through the careful selection of the most favorable combinations of TAAs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Kanojia, M. Garg, S. Gupta, A. Gupta, and A. Suri Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 630 - 639. [Abstract] [Full Text] [PDF]